Trials / Completed
CompletedNCT04019717
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination With Daclatasvir in Subjects With Chronic HCV Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-527 | Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase |
| DRUG | Daclatasvir | Inhibitor of HCV nonstructural protein 5A (NS5A) |
Timeline
- Start date
- 2019-06-20
- Primary completion
- 2020-01-29
- Completion
- 2020-03-23
- First posted
- 2019-07-15
- Last updated
- 2020-05-04
Locations
3 sites across 3 countries: Belgium, Mauritius, Moldova
Source: ClinicalTrials.gov record NCT04019717. Inclusion in this directory is not an endorsement.